Luhao Han

Luhao Han

Auto-generated profile, based on publicly available information

Luhao Han

School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Verified
Journal Article
Closed access
ZFZishui Fang
Zishui Fang
CJChengrui Jiang
Chengrui Jiang
YFYi Feng
Yi Feng
RCRixin Chen
Rixin Chen
XLXiaoying Lin
Xiaoying Lin
WJWeiying Jiang
Weiying Jiang

19 August 2019 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
JZJing Zhang
Jing Zhang
LHLuhao Han
Luhao Han
WLWei Li
Wei Li
QCQiaobin Chen
Qiaobin Chen
JLJie Lei
Jie Lei
SZSifan Zeng
Sifan Zeng
Recent evidence suggests early screening of preeclampsia and small-for-gestational-age (SGA) would benefit pregnancies followed by subsequent prophylactic use of aspirin. Multi-marker models have shown capability of predicting preeclampsia and SGA in first trimester. Yet the clinical feasibility of combined screening model for Chinese pregnancies has not been fully assessed. The aim of this study is to evaluate the applicability of a multi-marker screening model to the prediction of preeclampsia and SGA in first trimester particularly among Chinese population. Three thousand two hundred seventy pregnancies meeting the inclusion criteria took first-trimester screening of preeclampsia and SGA. A prior risk based on maternal characteristics was evaluated, and a posterior risk was assessed by combining prior risk with multiple of median (MoM) values of mean arterial pressure (MAP), serum placental growth factor (PLGF) and pregnancy associated plasma protein A (PAPP-A). Both risks were calculated by Preeclampsia PREDICTOR™ software, Perkin Elmer. Screening performance of prior and posterior risks for early and late preeclampsia by using PREDICTOR software was shown by Receiver Operating Characteristics (ROC) curves. The estimation of detection rates and false positive rates of delivery with both preeclampsia and SGA was made. Eight cases developed early preeclampsia (0.24%) and 35 were diagnosed as late preeclampsia (1.07%). Five with early preeclampsia and ten with late preeclampsia later delivered SGA newborns (0.46%); 84 without preeclampsia gave birth to the SGAs (2.57%). According to ROC curves, posterior risks performed better than prior risks in terms of preeclampsia, especially in early preeclampsia. At 10% false positive rate, detection rates of early and late preeclampsia were 87.50 and 48.57%, detection rates of early and late SGA were 41.67 and 28.00%, respectively. For SGA, detection rates in cases with preeclampsia were much higher than those in absence of it. This study demonstrates that combined screening model could be useful for predicting early preeclampsia in Chinese pregnancies. Furthermore, the performance of SGA screening by same protocol is strongly associated with preeclampsia.

1 April 2015 in Clinica Chimica Acta
Verified
Journal Article
Closed access
JTJia Tang
Jia Tang
CJChengrui Jiang
Chengrui Jiang
XXXiao Xiao
Xiao Xiao
ZFZishui Fang
Zishui Fang
LLLei Li
Lei Li
WJWeiying Jiang
Weiying Jiang

1 June 2016 in Journal of Structural Biology
Verified
Journal Article
Closed access
ZFZishui Fang
Zishui Fang
CJChengrui Jiang
Chengrui Jiang
JTJia Tang
Jia Tang
MHMing He
Ming He
XLXiaoying Lin
Xiaoying Lin
WJWeiying Jiang
Weiying Jiang

7 March 2016 in Hemoglobin
Verified
Journal Article
Closed access
PDF file
LHLuhao Han
Luhao Han
HSHai Su
Hai Su
HWHao Wu
Hao Wu
WJWeiying Jiang
Weiying Jiang
SCSuqin Chen
Suqin Chen
Glucose-6-phosphate dehydrogenase (G6PD) deficiency and thalassemia occur frequently in tropical and subtropical regions, while the prevalence of relationship between the two diseases in Xinjiang has not been reported. We aimed to determine the prevalence of these diseases and clarify the relationship between genotypes and phenotypes of the two diseases in the Uygur and Kazak ethnic groups in Xinjiang. We measured G6PD activity by G6PD:6PGD (glucose acid-6-phosphate dehydrogenase) ratio, identified the gene variants of G6PD and α- and β-globin genes by polymerase chain reaction (PCR)-DNA sequencing and gap-PCR and compared these variants in different ethnic groups in Xinjiang with those adjacent to it. Of the 149 subjects with molecular analysis of G6PD deficiency conducted, a higher prevalence of the combined mutations c.1311C > T/IVSXI + 93T > C and IVSXI + 93T > C, both with normal enzymatic activities, were observed in the Uygur and Kazak subjects. A case of rare mutation HBB: c.135delC [codon 44 (−C) in the heterozygous state], a heterozygous case of HBB: c.68A > G [Hb G-Taipei or β22(B4)Glu→Gly] and several common single nucleotide polymorphisms (SNPs) were found on the β-globin gene. In conclusion, G6PD deficiency with pathogenic mutations and three common α-thalassemia (α-thal) [– –SEA, −α3.7 (rightward), −α4.2 (leftward)] deletions and point mutations of the α-globin gene were not detected in the present study. The average incidence of β-thalassemia (β-thal) in Uygurs was 1.45% (2/138) in Xinjiang. The polymorphisms of G6PD and β-globin genes might be useful genetic markers to trace the origin and migration of the Uygur and Kazak in Xinjiang.

19 March 2026 in JMIR Preprints
Verified
Preprint
Open access
LHLuhao Han
Luhao Han
OHOlivia Holland
Olivia Holland
HRHasini Rathnayake
Hasini Rathnayake
CPCristiane Paganoti
Cristiane Paganoti
CRConrado Sávio Ragazini
Conrado Sávio Ragazini
FCFabrício Da Silva Costa
Fabrício Da Silva Costa
BACKGROUND Placental dysfunction underlies major obstetric complications, including preeclampsia, fetal growth restriction, preterm birth, and stillbirth. While early identification of pregnancies at high risk of complications enables preventive interventions, current screening methods based on traditional risk factors have limited accuracy. OBJECTIVE This project aims to develop robust prediction models for placental dysfunction-related pregnancy disorders and to determine the optimal delivery time by integrating maternal characteristics, biophysical measurements, and maternal circulating biomarkers. METHODS The Placental Health Study (PHS) is a prospective cohort study conducted at the Maternal Fetal Medicine (MFM) Unit at Gold Coast University Hospital (GCUH) in Queensland, Australia. Participants with singleton pregnancies enroll at one of three time points: 11–13 weeks, 26–28 weeks, and 35–36 weeks of gestation. Eligible participants who provide written informed consent are included and will also be invited to continue their participation through subsequent antenatal visits until delivery. Exclusion criteria are multiple pregnancies, major fetal anomalies, maternal age below 18 years, and inability to provide informed consent. Baseline and clinical data, including maternal demographics, obstetric and medical history, and current pregnancy records, will be collected. Each visit includes measuring maternal blood pressure and performing obstetric ultrasound with Doppler ultrasound to assess maternal, placental, and fetal indices and fetal biometry. Biological samples, including maternal serum, plasma, whole blood for RNA extraction, and urine, will be collected and processed for long-term storage at –80 ℃ for biomarker studies. Ethics approval has been granted by the Gold Coast Hospital and Health Service Human Research Ethics Committee (HREC/2022/QGC/84257) and Griffith University Human Research Ethics Committee (GU Ref No.2022/254). RESULTS Recruitment commenced in June 2022 and closed February 2026, with 1,267 participants enrolled, made up of 1,072 participants (84.6%) with a completed pregnancy and 144 participants (11.4%) still to complete their pregnancy, and the remaining 51 (4.0%) withdrawn or with missing/duplicated data. Clinical data have undergone preliminary cleaning and descriptive analysis, while biological samples are being processed for biomarker quantification and exploratory molecular analyses. Two to three publications are anticipated in late 2026 or early 2027, with ongoing analyses focused on biomarker discovery and integration with clinical and ultrasound parameters for prediction model development. CONCLUSIONS This cohort establishes a comprehensive database and biospecimen repository, collecting high-quality data and biological samples to advance research in predicting placental dysfunction-related pregnancy complications. Recruitment across three pregnancy stages integrates with routine clinical care, enhancing the feasibility and translation potential, while enabling the investigation of pregnancy progression and associated temporal changes. Although the single-center design may limit the sample size and generalizability of the findings to other settings and populations, the interdisciplinary research team brings diverse expertise that strengthens study depth and scope.